In vivo models of proliferative vitreoretinopathy
- PMID: 17401340
- DOI: 10.1038/nprot.2007.4
In vivo models of proliferative vitreoretinopathy
Abstract
We outline current in vitro and in vivo models for experimental proliferative vitreoretinopathy (PVR) and provide a detailed protocol of our standardized in vivo PVR model. PVR is the leading cause of failed surgical procedures for the correction of rhegmatogenous retinal detachment. The pathogenesis of this multifactorial condition is still not completely understood. Experimental models for PVR help us understand the factors that play a role in the pathogenesis of the disease process in a controlled manner and allow for reproducible preclinical assessment of novel therapeutic interventions. We describe a cell injection model in detail that uses homologous retinal pigment epithelial (RPE) cell cultures to induce PVR over a 2-8 week period.
Similar articles
-
Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3338-48. Invest Ophthalmol Vis Sci. 2002. PMID: 12356843
-
[The role of specific ROCK inhibitor in the prevention of experimental PVR in rabbits].Zhonghua Yan Ke Za Zhi. 2005 Dec;41(12):1112-8. Zhonghua Yan Ke Za Zhi. 2005. PMID: 16409766 Chinese.
-
Targeting of integrin-linked kinase with a small interfering RNA suppresses progression of experimental proliferative vitreoretinopathy.Exp Eye Res. 2008 Dec;87(6):551-60. doi: 10.1016/j.exer.2008.09.008. Epub 2008 Sep 27. Exp Eye Res. 2008. PMID: 18926819
-
[Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis].J Fr Ophtalmol. 2014 Sep;37(7):557-65. doi: 10.1016/j.jfo.2014.04.001. Epub 2014 Jul 2. J Fr Ophtalmol. 2014. PMID: 24997864 Review. French.
-
[Vitreoretinal proliferation. II. Pathogenic hypotheses].J Fr Ophtalmol. 1994;17(12):800-11. J Fr Ophtalmol. 1994. PMID: 7722243 Review. French.
Cited by
-
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.Am J Pathol. 2014 Nov;184(11):3052-68. doi: 10.1016/j.ajpath.2014.07.026. Epub 2014 Sep 26. Am J Pathol. 2014. PMID: 25261788 Free PMC article.
-
Assessment of the innate and adaptive immune system in proliferative vitreoretinopathy.Eye (Lond). 2012 Jun;26(6):872-81. doi: 10.1038/eye.2012.52. Epub 2012 Mar 30. Eye (Lond). 2012. PMID: 22460468 Free PMC article.
-
Mini drug pump for ophthalmic use.Curr Eye Res. 2010 Mar;35(3):192-201. doi: 10.3109/02713680903521936. Curr Eye Res. 2010. PMID: 20373877 Free PMC article.
-
Experimental Models to Study Epithelial-Mesenchymal Transition in Proliferative Vitreoretinopathy.Int J Mol Sci. 2023 Feb 24;24(5):4509. doi: 10.3390/ijms24054509. Int J Mol Sci. 2023. PMID: 36901938 Free PMC article. Review.
-
The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR).Graefes Arch Clin Exp Ophthalmol. 2011 Nov;249(11):1649-60. doi: 10.1007/s00417-011-1730-9. Epub 2011 Jul 7. Graefes Arch Clin Exp Ophthalmol. 2011. PMID: 21735240
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials